Protalix BioTherapeutics

Company Overview

Snapshot

Founded in January 1994, Protalix BioTherapeutics operates with 51–200 employees. The company has raised $159.9M across 11 funding rounds from 5 investors. In February 2021, Protalix BioTherapeutics completed a public offering, raising approximately $40 million in gross proceeds.

Business overview

Protalix BioTherapeutics is a biopharmaceutical company specializing in the development, production, and commercialization of recombinant therapeutic proteins. The company utilizes its proprietary ProCellEx plant-cell-based protein expression system to create potentially clinically superior versions of therapeutic proteins for established pharmaceutical markets. Its core technology focuses on plant-based protein expression, addressing genetic disorders and inflammatory diseases within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In September 2024, Protalix BioTherapeutics announced the repayment of outstanding senior secured convertible promissory notes. This action signals a strengthening financial position and reduced debt obligations, which can enhance investor confidence and provide greater financial flexibility for future strategic initiatives and drug development programs within the biopharmaceutical sector.

Company Intelligence Q&A

What was a key financial event for Protalix BioTherapeutics in February 2021?

In February 2021, Protalix BioTherapeutics completed a public offering, raising approximately $40 million in gross proceeds.

What was the strategic announcement made by Protalix BioTherapeutics in September 2024?

In September 2024, Protalix BioTherapeutics announced the repayment of outstanding senior secured convertible promissory notes.

What was a significant partnership for Protalix BioTherapeutics in October 2015?

In October 2015, Protalix BioTherapeutics secured an investment from Pfizer, which also involved commercial rights for its Gaucher drug.

What was a key leadership appointment for Protalix BioTherapeutics in September 2023?

In September 2023, Protalix BioTherapeutics appointed Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors.

What was a significant clinical trial milestone for Protalix BioTherapeutics in September 2019?

In September 2019, Protalix BioTherapeutics and Chiesi Group completed enrollment in the third Phase III clinical trial of pegunigalsidase alfa (PRX‑102) for the treatment of Fabry Disease.